Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titer

Molecular Therapy

Volumn 2, Issue 3, 2000, Pages 262-275

  Sheridan, Philip L ^a   Bodner, Mordechai ^a   Lynn, Andrea ^a   Phuong, Trung K ^a,b   DePolo, Nicholas J ^a   De La Vega Jr , Daniel J ^a   O'Dea, Joanne ^a   Nguyen, Kathy ^a   McCormack, James E ^a,c   Driver, David A ^a   Townsend, Kay ^a   Ibañez, Carlos E ^a   Sajjadi, Nancy C ^a   Greengard, Judith S ^a,d   Moore, Margaret D ^a,e   Respess, James ^a   Chang, Stephen M W ^a,f   Dubensky Jr , Thomas W ^a   Jolly, Douglas J ^a   Sauter, Sybille L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Elitra Pharmaceuticals   (United States)

^c Paik Inje Memorial Institute   (United States)

^d AMGEN INC   (United States)

^e ZYMOGENETICS INC   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

High titer; Packaging cell line; RCR potential; Reduced homology; Retroviral vectors

Indexed keywords

UNIDENTIFIED RETROVIRUS;

BLOOD CLOTTING FACTOR 8; PRIMER DNA;

ARTICLE; CELL LINE; GENE VECTOR; GENETICS; HEMOPHILIA A; HUMAN; NUCLEOTIDE SEQUENCE; RETROVIRUS; VIRUS ASSEMBLY;

BASE SEQUENCE; CELL LINE; DNA PRIMERS; FACTOR VIII; GENETIC VECTORS; HEMOPHILIA A; HUMANS; RETROVIRIDAE; VIRUS ASSEMBLY;

EID: 0034264583     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0123     Document Type: Article

References (56)

1. Human Gene Marker/Therapy Clinical Protocols (1999). Hum. Gene Ther. 10: 3067-3123.
2. VandenDriessche, T., et al. (1999). Long-term expression of human coagulation Factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in Factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA 96: 10379-10384.
3. Nemuniatis, J., et al. (1999). Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum. Gene Ther. 10: 1289-1298.
4. Karavodin, L. M., et al. (1998). Generation of a systemic anti-tumor response with regional intratumoral injections of interferon γ retroviral vector. Hum. Gene Ther. 9: 2231-2241.
5. Greengard, J. S., and Jolly, D. J. (1999). Animal testing of retroviral-mediated gene therapy for Factor VIII deficiency. Thromb. Haemost. 82: 555-561.
6. Sallberg, M., et al. (1998). Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding hepatitis B virus core antigen. Hum. Gene Ther. 9: 1719-1729.
7. Ghivizzani, S. C., et al. (1997). Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: Implications for arthritis gene therapy. Gene Ther. 4: 977-982.
8. Wang, G., et al. (1998). Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia. J. Virol. 72: 9818-9826.
9. Sajjadi, N. (1997). Development of retroviral-based gene therapy products: A quality control perspective. Qual. Assur. J. 2: 113-117.
10. Cone, R. D., and Mulligan, R. C. (1984). High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range. Proc. Natl. Acad. Sci. USA 81: 6349-6353.
11. Miller, A. D., and Buttimore, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Gell. Biol. 6: 2895-2902.
12. Miller, A. D. (1992). Retroviral vectors. Gurr. Top. Microbiol. Immunol. 158: 1-24.
13. Danos O., and Mulligan, R. C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85: 6460-6464.
14. Rigg, R. J., Chen, J., Dando, J. S., Forestall, S. P., Plevac, I., and Bohnlein, E. (1996). A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety. Virology 218: 290-195.
15. Yu, S. F., et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83: 3194-3198.
16. Chong, H., and Vile, R. G. (1996). Replication-competent retrovirus produced a "split-function" third generation amphotropic packaging cell line. Gene Ther. 3: 624-629.
17. Chong, H., Starkey, W., and Vile, R. G. (1998). A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J. Virol. 72: 2663-2670.
18. Yoshimatsu, T., Tamura, M., Kuriyama, S., and Ikenaka, K. (1998). Improvement of retroviral packaging cell lines by introducing the polyoma virus early region. Hum. Gene Ther. 9: 161-172.
19. Forestell, S. P., Dando, J. S., Chen, J., de Vries, P., Boehnlein, E., and Rigg, R. J. (1997). Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer. Gene Ther. 4: 600-610.
20. Bestwick, R. K., Kozak, S. L, and Kabat, D. (1988). Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc. Natl. Acad. Sci. USA 85: 5404-5408.
21. Lynch, C. M., and Miller, A. D. (1991). Production of high-titer helper virus-free retroviral vectors by co-cultivation of packaging cells with different host ranges. J. Virol. 65: 3887-3890.
22. Muenchau, D. D., Freeman, S. M., Cornetta, K., Zwiebel, J. A., and Anderson, W. F. (1990). Analysis of retroviral packaging cell lines for generation of replication-competent virus. Virology 176: 262-265.
23. Kim, Y. S., Lim, H. K., and Kim, K. J. (1998). Production of high-titer retroviral vectors and detection of replication-competent retroviruses. Mol. Cells 8: 36-42.
24. Kinsella, T. M., and Nolan, G. P. (1996). Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7: 1405-1413.
25. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90: 8392-8396.
26. Barber, J. R., Jolly, D. J., Respess, J. G., and Chang, S. M. W. (1997). Retroviral packaging cell lines. U.S. Patent No. 5,591,624.
27. DePolo, N. J., et al. (1999). The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73: 6708-6714.
28. Irwin, M. J., et al. (1994). Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J. Virol. 68: 5036-5044.
29. Pittman, D. D., Marquette, K. A., and Kaufman, R. J. (1994). Role of B domain for Factor VIII and Factor V expression and function. Blood84: 4214-4225.
30. Pittman, D. D., et al. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted Factor VIII. Blood 81: 2925-2935.
31. Lind, P., et al. (1995). Novel forms of B-domain-deleted recombinant Factor VIII molecules. Construction and biochemical characterization. Eur. J. Biochem. 232: 19-27.
32. O'Neill, R. R., Buckler, C. E., Theodore, T. S., Martin, M. A., and Repaske, R. (1985). Envelope and long terminal repeat sequences of a cloned infectious NZB xenotropic murine leukemia virus. J. Virol. 53: 100-106.
33. Chattopadhyay, S. K., Oliff, A. I., Linemeyer, D. L., Lander, M. R., and Lowy, D. R. (1981). Genomes of murine leukemia viruses isolated from wild mice. J. Virol. 39: 777-791.
34. Yee, Y.-K., Friedmann, T., and Burns, J. C. (1994). Generation of high-titer pseudo-typed retroviral vectors with very broad host range. Methods Cell Biol. 43: 99-112.
35. Laube, L. S., et al. (1994). Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum. Gene Ther. 5: 853-862.
36. Jolly, D. (1994). Viral vector systems for gene therapy. Cancer Gene Ther. 1: 51-64.
37. Boyle, D. L., et al. (1999). Intra-cellular IL-4 gene therapy in arthritis: Anti-inflammatory effects and enhanced Th2 activity. Gene Ther. 6: 1911-1918.
38. Wang, G., et al. (1999). Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J. Clin. Invest. 104: R55-R62.
39. Printz, M., Reynolds, J., Mento, S. J., Jolly, D., Kowal, K., and Sajjadi, N. (1995). Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Ther. 2: 143-150.
40. Roth, M. J. (1991). Mutational analysis of the carboxyl terminus of the Moloney murine leukemia virus integration protein. J. Virol. 65: 2141-2145.
41. Morgenstern, J. P., and Land, H. (1990). Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587-3596.
42. Otto, E., et al. (1994). Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum. Gene Ther. 5: 567-575.
43. Norman, J. A., Hobart, P., Manthorpe, M., Feigner, P., and Wheeler, C. (1997). Development of improved vectors for DMA-based immunization and other gene therapy applications. Vaccine 15: 801-803.
44. Rasheed, S., Gardner, M. B., and Chan, E. (1976). Amphotropic host range of naturally occurring wild mouse leukemia viruses. J. Virol. 19: 13-18.
45. Markowitz, D., Goff, S., and Bank, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406.
46. Onodera, M., Yachie, A., Nelson, D. M., Welchlin, H., Morgan, R. A., and Blaese, R. M. (1997). A simple and reliable method for screening retroviral producer clones without selectable markers. Hum. Gene Ther. 8: 1189-1194.
47. Miller, A. D., and Rosman, G. J. (1989). Improved retroviral vectors for gene transfer and expression. BioTechniques 7: 980-990.
48. Bender, M. A., Palmer, T. D., Gelinas, R. E., and Miller, A. D. (1987). Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol. 61: 1639-1646.
49. Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., and Verma, I. M. (1999). A packaging cell line for lentivirus vectors. J. Virol. 73: 576-584.
50. Rasheed, S., Gardner, M. B., and Chan, E. (1976). Amphotropic host range of naturally occurring wild mouse leukemia viruses. J. Virol. 19: 13-18.
51. Pensiero, M. N., Wysocki, C. A., Nader, K., and Kikuchi, G. E. (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7: 1095-1101.
52. Bodine, D. M., et al. (1990). Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 87: 3738-3742.
53. Xu, L., et al. (1994). Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol. Exp. Hematol. 22: 223-230.
54. Sun, J. Y., et al. (1997). Construction of retroviral vectors carrying human CD3γcDNA and reconstitution of CD3γ expression and T cell receptor surface expression and function in a CD3γ-deficient mutant T cell line. Hum. Gene Ther. 8: 1041-1048.
55. Persons, D. A., Mehaffey, M. G., Kaleko, M., Nienhuis, A. W., and Vanin, E. F. (1998). An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol. Dis. 24: 167-182.
56. Fong, T. C., Sauter, S. L., Ibanez, C. E., Sheridan, P. L., and Jolly, D. J. (2000). The use and development of retroviral vectors to deliver cytokine genes for cancer therapy. Crit. Rev. Ther. Drug Carrier Systems 17: 1-60.